{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:10:53Z","timestamp":1767237053194,"version":"build-2065373602"},"reference-count":188,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MECONC\/ 29043\/2017","SFRH\/BD\/132751\/2017"],"award-info":[{"award-number":["PTDC\/MECONC\/ 29043\/2017","SFRH\/BD\/132751\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In the last years, we have witnessed remarkable advances in targeted therapies for cancer patients. There is a growing effort to either replace or reduce the dose of unspecific, systemic (chemo)therapies, given the associated short- and long-term side effects, by introducing more specific targeted therapies as single or combination agents. Due to the well-known implications of the immune system and epigenetic landscape in modulating cancer development, both have been explored as potential targets in several malignancies, including those affecting the genitourinary tract. As the immune system function is also epigenetically regulated, there is rationale for combining both strategies. However, this is still rather underexplored, namely in urological tumors. We aim to briefly review the use of immune therapies in prostate, kidney, bladder, and testicular cancer, and further describe studies providing supporting evidence on their combination with epigenetic-based therapies.<\/jats:p>","DOI":"10.3390\/ijms21030829","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T09:37:09Z","timestamp":1580204229000},"page":"829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting the Immune system and Epigenetic Landscape of Urological Tumors"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"first","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051415816674103","article-title":"The Epidemiology of urological cancer 2001\u20132013","volume":"10","author":"Kockelbergh","year":"2017","journal-title":"J. Clin. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bju.13875","article-title":"Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality","volume":"120","author":"Greiman","year":"2017","journal-title":"BJU Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global Burden of Urologic Cancers, 1990\u20132013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_7","unstructured":"Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2018). Global Cancer Observatory: Cancer Tomorrow, IARC."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic Burden of Bladder Cancer Across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Moch, H., Ulbright, T., Humphrey, P., and Reuter, V. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs, IARC. [4th ed.].","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/BLC-150010","article-title":"Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years","volume":"1","author":"Raghavan","year":"2015","journal-title":"Bladder Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.eururo.2018.11.014","article-title":"MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges","volume":"75","author":"Henrique","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/era.11.201","article-title":"Molecular mechanisms of cisplatin resistance in bladder cancer","volume":"12","author":"Drayton","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","article-title":"Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications","volume":"9","author":"Joseph","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"70982","DOI":"10.18632\/oncotarget.20237","article-title":"Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","article-title":"Mutational Landscape and Sensitivity to Immune Checkpoint Blockers","volume":"22","author":"Chabanon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1586\/14737140.2015.961430","article-title":"Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: Current strategies","volume":"15","author":"Wang","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_26","first-page":"65","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res. Rep. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40265-017-0748-7","article-title":"Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives","volume":"77","author":"Farina","year":"2017","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/14737140.2018.1432357","article-title":"Nivolumab for the treatment of urothelial cancers","volume":"18","author":"Teo","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/PAS.0000000000001084","article-title":"PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma","volume":"42","author":"Hodgson","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.eururo.2018.11.002","article-title":"PD-L1 Antibody Comparison in Urothelial Carcinoma","volume":"75","author":"Rijnders","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/TCRM.S158753","article-title":"Immune checkpoint inhibitors in urothelial cancer: Recent updates and future outlook","volume":"14","author":"Gopalakrishnan","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Davarpanah, N.N., Yuno, A., Trepel, J.B., and Apolo, A.B. (2017). Immunotherapy: A new treatment paradigm in bladder cancer. Curr. Opin. Oncol.","DOI":"10.1097\/CCO.0000000000000366"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-018-0496-x","article-title":"Urine cell-based DNA methylation classifier for monitoring bladder cancer","volume":"10","author":"Mengual","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2009.07.041","article-title":"Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples","volume":"58","author":"Renard","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/bjc.2016.454","article-title":"MicroRNA promoter methylation: A new tool for accurate detection of urothelial carcinoma","volume":"116","author":"Padrao","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Larsen, L.K., Lind, G.E., Guldberg, P., and Dahl, C. (2019). DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies. Int J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112657"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2017.10.004","article-title":"The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review","volume":"61","author":"Casadevall","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11934-018-0861-5","article-title":"Epigenetic Alterations in Bladder Cancer","volume":"19","author":"Porten","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Monteiro-Reis, S., Lobo, J., Henrique, R., and Jeronimo, C. (2019). Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020297"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1038\/srep08293","article-title":"Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12935-014-0149-x","article-title":"EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells","volume":"15","author":"Cui","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cao, Y.P., Sun, J.Y., Li, M.Q., Dong, Y., Zhang, Y.H., Yan, J., Huang, R.M., and Yan, X. (2019). Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. Acta Pharmacol. Sin.","DOI":"10.1038\/s41401-018-0205-5"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e0138390","DOI":"10.1371\/journal.pone.0138390","article-title":"G9a Inhibition Induces Autophagic Cell Death via AMPK\/mTOR Pathway in Bladder Transitional Cell Carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"37335","DOI":"10.18632\/oncotarget.6135","article-title":"Honokiol inhibits bladder tumor growth by suppressing EZH2\/miR-143 axis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ijc.20634","article-title":"Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo","volume":"113","author":"Canes","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1442-2042.2006.01344.x","article-title":"Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest","volume":"13","author":"Li","year":"2006","journal-title":"Int. J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Byler, T.K., Leocadio, D., Shapiro, O., Bratslavsky, G., Stodgell, C.J., Wood, R.W., Messing, E.M., and Reeder, J.E. (2012). Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol., 12.","DOI":"10.1186\/1471-2490-12-21"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.juro.2011.07.107","article-title":"Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro","volume":"186","author":"Deb","year":"2011","journal-title":"J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.juro.2010.10.034","article-title":"The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line","volume":"185","author":"Yoon","year":"2011","journal-title":"J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.radonc.2013.06.021","article-title":"Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression","volume":"108","author":"Groselj","year":"2013","journal-title":"Radiother Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-16-3232","article-title":"E3 Ligase cIAP2 Mediates Downregulation of MRE11 and Radiosensitization in Response to HDAC Inhibition in Bladder Cancer","volume":"77","author":"Nicholson","year":"2017","journal-title":"Cancer Res."},{"key":"ref_54","first-page":"421","article-title":"Cancer-testis antigen expression in bladder cancer","volume":"16","author":"Fradet","year":"2006","journal-title":"Prog. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2012.05.050","article-title":"Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guerin response in patients with high-grade non-muscle-invasive bladder carcinoma","volume":"63","author":"Cebrian","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5507\/bp.2017.008","article-title":"Methylation status as a predictor of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor","volume":"161","author":"Husek","year":"2017","journal-title":"Biomed. Pap."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-018-0536-6","article-title":"Increased CD4(+) T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients","volume":"10","author":"Hartana","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cei.13183","article-title":"Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer","volume":"194","author":"Hartana","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1089\/hum.2018.048","article-title":"Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout","volume":"29","author":"Zhen","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1055-9965.EPI-16-0461","article-title":"DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes","volume":"26","author":"Koestler","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41418-019-0278-9","article-title":"Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer","volume":"26","author":"Ramakrishnan","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","article-title":"Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"25","author":"Segovia","year":"2019","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/s41419-017-0024-5","article-title":"Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer","volume":"8","author":"Ramakrishnan","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M611686200","article-title":"Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia","volume":"282","author":"Lasbury","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Hodgson, A., Jungbluth, A.A., Katabi, N., Xu, B., and Downes, M.R. (2019). Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder. Virchows Arch.","DOI":"10.1007\/s00428-019-02661-2"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.18632\/oncotarget.14176","article-title":"Inhibition of long non-coding RNA UCA1 by CRISPR\/Cas9 attenuated malignant phenotypes of bladder cancer","volume":"8","author":"Zhen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4161\/cbt.10.7.13247","article-title":"Signaling pathways in renal cell carcinoma","volume":"10","author":"Banumathy","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CCO.0000000000000186","article-title":"Molecular pathways in renal cell carcinoma: Recent advances in genetics and molecular biology","volume":"27","author":"Su","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMe068263","article-title":"Renal-cell carcinoma--molecular pathways and therapies","volume":"356","author":"Brugarolas","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.seminoncol.2006.06.001","article-title":"Molecular pathways in renal cell carcinoma--rationale for targeted treatment","volume":"33","author":"Kim","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1016\/j.celrep.2018.06.032","article-title":"The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2017.08.010","article-title":"Systemic treatment of renal cell cancer: A comprehensive review","volume":"60","author":"Kempf","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2016-0435","article-title":"Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation","volume":"22","author":"Bamias","year":"2017","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11523-016-0463-4","article-title":"Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action","volume":"12","author":"Duran","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40425-019-0621-1","article-title":"Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma","volume":"7","author":"Ghatalia","year":"2019","journal-title":"J. Immunother Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/cas.13996","article-title":"Immune infiltration in renal cell carcinoma","volume":"110","author":"Zhang","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"736.e18","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An Immune Atlas of Clear Cell Renal Cell Carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"964.e31","DOI":"10.1016\/j.cell.2019.10.007","article-title":"Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma","volume":"179","author":"Clark","year":"2019","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lameirinhas, A., Miranda-Goncalves, V., Henrique, R., and Jeronimo, C. (2019). The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma. Genes, 10.","DOI":"10.3390\/genes10040264"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2217\/imt-2016-0111","article-title":"Epigenetic regulation of immune checkpoints: Another target for cancer immunotherapy?","volume":"9","author":"Ali","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"22","author":"Atzpodien","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J. Immunother Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"212528","DOI":"10.7573\/dic.212528","article-title":"Immunotherapy in renal cell carcinoma: Latest evidence and clinical implications","volume":"7","author":"Santoni","year":"2018","journal-title":"Drugs Context."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","article-title":"Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: A randomised, open-label, phase 3 trial","volume":"17","author":"Cella","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1634\/theoncologist.2018-0267","article-title":"The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma","volume":"24","author":"Calvo","year":"2019","journal-title":"Oncologist"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"McKay, R.R., Bosse, D., and Choueiri, T.K. (2018). Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. J. Clin. Oncol., JCO2018790253.","DOI":"10.1200\/JCO.2018.79.0253"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11523-015-0392-7","article-title":"Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis","volume":"11","author":"Iacovelli","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): A multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e2004","DOI":"10.1097\/MD.0000000000002004","article-title":"Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15592294.2017.1385685","article-title":"SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization","volume":"12","author":"Ferreira","year":"2017","journal-title":"Epigenetics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41585-018-0023-z","article-title":"Epigenetics in renal cell cancer: Mechanisms and clinical applications","volume":"15","author":"Joosten","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1541-7786.MCR-17-0636","article-title":"Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis","volume":"17","author":"Nam","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1158\/1078-0432.CCR-04-1155","article-title":"Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model","volume":"11","author":"Touma","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Jones","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels","volume":"16","author":"Mahalingam","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_100","first-page":"3161","article-title":"HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells","volume":"32","author":"Kim","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Sato, A., Asano, T., Isono, M., Ito, K., and Asano, T. (2014). Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC Urol., 14.","DOI":"10.1186\/1471-2490-14-71"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2012.05.003","article-title":"Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells","volume":"324","author":"Juengel","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-06-0883","article-title":"Phase I trial of sequential low-dose 5-aza-2\u2032-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma","volume":"12","author":"Gollob","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2005.03.4074","article-title":"Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation","volume":"24","author":"Reu","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-07-0014","article-title":"Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma","volume":"13","author":"Kato","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00345-010-0582-y","article-title":"Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha","volume":"29","author":"Juengel","year":"2011","journal-title":"World J. Urol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-17-1178","article-title":"Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I\/II Trial (NCI-CTEP#7870)","volume":"23","author":"Pili","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K.M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R., and Pili, R. (2012). Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030815"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1758834017719215","article-title":"Prognostic and predictive biomarkers in prostate cancer: Latest evidence and clinical implications","volume":"9","author":"Terada","year":"2017","journal-title":"Ther. Adv. Med. Oncol"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.urolonc.2017.10.028","article-title":"High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer","volume":"36","author":"Lobo","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_113","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/bjc.2016.86","article-title":"Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome","volume":"114","author":"Berney","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2016.07.006","article-title":"Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets","volume":"166","author":"Ramalingam","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1534735404270757","article-title":"Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy","volume":"3","author":"McCarty","year":"2004","journal-title":"Integr. Cancer Ther."},{"key":"ref_118","first-page":"6063","article-title":"Molecular and cellular mechanisms of castration resistant prostate cancer","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","article-title":"Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level","volume":"67","author":"Karantanos","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","article-title":"The Tumor Immune Contexture of Prostate Cancer","volume":"10","author":"Vitkin","year":"2019","journal-title":"Front. Immunol"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jnci\/djy141","article-title":"The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target","volume":"111","author":"Zhao","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/ERC-19-0420","article-title":"The epigenetic and transcriptional landscape of neuroendocrine prostate cancer","volume":"27","author":"Davies","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1586\/14760584.2015.1099437","article-title":"Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions","volume":"14","author":"Wei","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_125","first-page":"16","article-title":"The role of immunotherapy in prostate cancer: An overview of current approaches in development","volume":"11","author":"Risk","year":"2009","journal-title":"Rev. Urol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/CCO.0000000000000281","article-title":"The evolving role of immunotherapy in prostate cancer","volume":"28","author":"Cordes","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Schepisi, G., Farolfi, A., Conteduca, V., Martignano, F., De Lisi, D., Ravaglia, G., Rossi, L., Menna, C., Bellia, S.R., and Barone, D. (2017). Immunotherapy for Prostate Cancer: Where We Are Headed. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122627"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184\u2013043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Baumgart, S.J., and Haendler, B. (2017). Exploiting Epigenetic Alterations in Prostate Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051017"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2004.06.014","article-title":"Molecular detection of prostate cancer: A role for GSTP1 hypermethylation","volume":"46","author":"Henrique","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13148-019-0716-z","article-title":"Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging","volume":"11","author":"Bakavicius","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly, E., Tuzova, A.V., Walsh, A.L., Russell, N.M., O\u2019Brien, O., Kelly, S., Dhomhnallain, O.N., DeBarra, L., Dale, C.M., and Brugman, R. (2019). epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. JCO Precis. Oncol., 2019.","DOI":"10.1200\/PO.18.00134"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7754\/Clin.Lab.2013.130701","article-title":"Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis","volume":"60","author":"Dumache","year":"2014","journal-title":"Clin. Lab."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fonc.2019.00900","article-title":"Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction","volume":"9","author":"Bidarra","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2017.08.011","article-title":"MicroRNAs in prostate cancer: Functional role as biomarkers","volume":"407","author":"Kanwal","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/pcan.2016.21","article-title":"Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells","volume":"19","author":"Gupta","year":"2016","journal-title":"Prostate Cancer Prostatic. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1677\/ERC-08-0130","article-title":"Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models","volume":"16","author":"Festuccia","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10637-017-0529-x","article-title":"Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer","volume":"36","author":"Park","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","article-title":"Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer","volume":"19","author":"Urbanucci","year":"2017","journal-title":"Cell Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1158\/0008-5472.CAN-04-4316","article-title":"IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression","volume":"65","author":"Dunn","year":"2005","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s40425-019-0758-y","article-title":"Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition","volume":"7","author":"Mao","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/pros.22525","article-title":"Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion","volume":"72","author":"Hudak","year":"2012","journal-title":"Prostate"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1541-7786.MCR-18-0638","article-title":"Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression","volume":"17","author":"Lerman","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1158\/0008-5472.CAN-10-0427","article-title":"Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells","volume":"70","author":"Song","year":"2010","journal-title":"Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.18632\/oncotarget.7180","article-title":"Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells","volume":"7","author":"Gameiro","year":"2016","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"52115","DOI":"10.18632\/oncotarget.10313","article-title":"Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection","volume":"7","author":"Danziger","year":"2016","journal-title":"Oncotarget"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"53309","DOI":"10.18632\/oncotarget.10786","article-title":"CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients","volume":"7","author":"Goltz","year":"2016","journal-title":"Oncotarget"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"84359","DOI":"10.18632\/oncotarget.12711","article-title":"Inducible expression of cancer-testis antigens in human prostate cancer","volume":"7","author":"Heninger","year":"2016","journal-title":"Oncotarget"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Lee, J., Han, J.H., Jang, A., Kim, J.W., Hong, S.A., and Myung, S.C. (2016). DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166664"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","article-title":"The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression","volume":"36","author":"Su","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pros.23275","article-title":"Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model","volume":"77","author":"Sulek","year":"2017","journal-title":"Prostate"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5306\/wjco.v4.i1.4","article-title":"Development of animal models underlining mechanistic connections between prostate inflammation and cancer","volume":"4","author":"Mimeault","year":"2013","journal-title":"World J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1038\/oncsis.2017.16","article-title":"Twist1\/Dnmt3a and miR186 establish a regulatory circuit that controls inflammation-associated prostate cancer progression","volume":"6","author":"Zhao","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2174\/15680266113136660197","article-title":"New and highly potent antitumor natural products from marine-derived fungi: Covering the period from 2003 to 2012","volume":"13","author":"Pejin","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1080\/14786419.2014.921686","article-title":"An insight into the cytotoxic activity of phytol at in vitro conditions","volume":"28","author":"Pejin","year":"2014","journal-title":"Nat. Prod. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14786419.2013.863201","article-title":"Further in vitro evaluation of cytotoxicity of the marine natural product derivative 4\u2032-leucine-avarone","volume":"28","author":"Pejin","year":"2014","journal-title":"Nat. Prod. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fct.2019.05.016","article-title":"Paederia foetida induces anticancer activity by modulating chromatin modification enzymes and altering pro-inflammatory cytokine gene expression in human prostate cancer cells","volume":"130","author":"Pradhan","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1387\/ijdb.130017ll","article-title":"Role of epigenetics in the etiology of germ cell cancer","volume":"57","author":"Stoop","year":"2013","journal-title":"Int J. Dev. Biol"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2014.07.003","article-title":"An oncofetal and developmental perspective on testicular germ cell cancer","volume":"29","author":"Rijlaarsdam","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., Jeronimo, C., Henrique, R., and Looijenga, L.H.J. (2019). Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020258"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","article-title":"Testicular germ cell tumors: Revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists","volume":"82","author":"Lobo","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41568-019-0178-9","article-title":"Human germ cell tumours from a developmental perspective","volume":"19","author":"Oosterhuis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.celrep.2018.05.039","article-title":"Integrated Molecular Characterization of Testicular Germ Cell Tumors","volume":"23","author":"Shen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/epi-2016-0081","article-title":"The epigenetics of testicular germ cell tumors: Looking for novel disease biomarkers","volume":"9","author":"Costa","year":"2017","journal-title":"Epigenomics"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc3634","article-title":"Survivors of childhood and adolescent cancer: Life-long risks and responsibilities","volume":"14","author":"Robison","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Bakardjieva-Mihaylova, V., Skvarova Kramarzova, K., Slamova, M., Svaton, M., Rejlova, K., Zaliova, M., Dobiasova, A., Fiser, K., Stuchly, J., and Grega, M. (2019). Molecular Basis of Cisplatin Resistance in Testicular Germ Cell Tumors. Cancers (Basel), 11.","DOI":"10.3390\/cancers11091316"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"21794","DOI":"10.18632\/oncotarget.15585","article-title":"Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors","volume":"8","author":"Chovanec","year":"2017","journal-title":"Oncotarget"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Lobo, J., Rodrigues, A., Guimaraes, R., Cantante, M., Lopes, P., Mauricio, J., Oliveira, J., Jeronimo, C., and Henrique, R. (2019). Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1\/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers, 11.","DOI":"10.3390\/cancers11101535"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14\u2013206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2018.09.010","article-title":"An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis","volume":"75","author":"Necchi","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Lobo, J., Henrique, R., and Jeronimo, C. (2018). The Role of DNA\/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors. Cancers, 11.","DOI":"10.3390\/cancers11010006"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1101\/gr.201293.115","article-title":"Imprints and DPPA3 are bypassed during pluripotency- and differentiation-coupled methylation reprogramming in testicular germ cell tumors","volume":"26","author":"Killian","year":"2016","journal-title":"Genome. Res."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Lobo, J., Nunes, S.P., Gillis, A.J.M., Barros-Silva, D., Miranda-Goncalves, V., Berg, A.V.D., Cantante, M., Guimaraes, R., Henrique, R., and Jeronimo, C. (2019). XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality. Cancers (Basel), 11.","DOI":"10.3390\/cancers11091385"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(03)15170-7","article-title":"XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer","volume":"363","author":"Kawakami","year":"2004","journal-title":"Lancet"},{"key":"ref_180","first-page":"1","article-title":"Liquid biopsy in germ cell tumors: Biology and clinical management","volume":"3","author":"Chovanec","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"11295","DOI":"10.1073\/pnas.94.21.11295","article-title":"A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells","volume":"94","author":"Minucci","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.20918","article-title":"The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression","volume":"50","author":"Nettersheim","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/andr.12611","article-title":"Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: Past, present, and future considerations","volume":"7","author":"Oing","year":"2019","journal-title":"Andrology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/modpathol.2013.183","article-title":"Cancer testis antigen expression in testicular germ cell tumorigenesis","volume":"27","author":"Bode","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","article-title":"Epigenetics and immunotherapy: The current state of play","volume":"87","author":"Dunn","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coph.2017.05.006","article-title":"Epigenetic modulation in cancer immunotherapy","volume":"35","author":"Gallagher","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Gatla, H.R., Muniraj, N., Thevkar, P., Yavvari, S., Sukhavasi, S., and Makena, M.R. (2019). Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051110"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Banik, D., Moufarrij, S., and Villagra, A. (2019). Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092241"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:44:46Z","timestamp":1760363086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":188,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21030829"],"URL":"https:\/\/doi.org\/10.3390\/ijms21030829","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2020,1,28]]}}}